Regeneron Pharmaceuticals, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
REGN Nasdaq 2830 www.regeneron.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Regeneron Pharmaceuticals, Inc.

Regeneron’s Billion-Dollar Catalyst Flying Under Wall Street’s Radar Ahead of Oct. 30 Earnings - Oct 26th, 2026 7:39 am
Analysts Estimate Jazz Pharmaceuticals (JAZZ) to Report a Decline in Earnings: What to Look Out for - Oct 26th, 2026 7:00 am
Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. Preparedness - Oct 26th, 2026 5:00 am
Can Incyte Stock Hit $170? - Oct 26th, 2026 4:13 am
Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) - Oct 25th, 2026 3:15 am
Vertex Stock Looks Expensive. Does It Get Cheaper Ahead? - Oct 23rd, 2026 11:29 am
1 safe-and-steady stock with exciting potential and 2 facing headwinds - Oct 23rd, 2026 10:56 am
Regeneron (REGN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Oct 23rd, 2026 7:00 am
Gilead Sciences (GILD) vs. AMGN and VRTX: Can Oncology Growth and HIV Strength Drive a New Growth Era Beyond Acquisitions? - Oct 22nd, 2026 2:33 pm
Are You Overpaying For Regeneron Stock Versus Its Rivals? - Oct 21st, 2026 3:18 pm
Why Should You Think About Vertex Differently Now? - Oct 20th, 2026 6:56 pm
EyePoint halves workforce and ends Phase III trial early after endpoint miss - Oct 20th, 2026 5:37 am
Strong Dupixent Trajectory Anchors Regeneron Pharmaceuticals’ (REGN) Solid Financial Results - Oct 19th, 2026 8:16 pm
How Much Upside Is Left In Regeneron Stock? - Oct 19th, 2026 11:16 am
Forget Eli Lilly and Novo: This Biotech Could Be a Surprising Winner in the Weight Loss Market - Oct 19th, 2026 8:44 am
Can Zenkuda's Multi-Indication Potential Drive KOD Stock Higher? - Oct 19th, 2026 6:10 am
Sensorion Announces the Appointment of Peter Weber, MD, MBA, as Chief Medical Officer - Oct 19th, 2026 2:28 am
Forget Eylea: Regeneron's Real Value May Be Hiding in Its Dupixent Profit Share - Oct 17th, 2026 1:44 pm